At eFFECTOR Therapeutics, we possess an unrelenting drive to improve outcomes for patients with cancer.

This is why we are pioneering the development of selective translation regulator inhibitors (STRIs): a new class of cancer therapies designed to overcome cancer’s complexity.
Cancer cells rely on a burst of protein synthesis to multiply and survive.


STRIs simultaneously block production of multiple disease-driving proteins as a single drug. This is possible through targeting a central node (eIF4F) where two major cancer signaling pathways converge and activate a burst of protein synthesis that drives multiple disease processes.

In cancer, processes that are normally tightly controlled become dysregulated, including translation. This leads to the aberrantly high production of multiple proteins that cause uncontrolled growth, immune evasion and metastasis. We believe that our STRIs can inhibit the production of key disease-driving proteins, which tumors have hijacked for their benefit, all while preserving the cell’s normal, healthy state. Our STRIs, which can be synergistic with existing therapies and those in development, are specifically designed to block production of oncoproteins, immune suppression factors and resistance mechanisms that cancer uses to evade therapeutic intervention.

eFFECTOR was founded on pioneering research in the laboratories of Drs. Davide Ruggero and Kevan Shokat and subsequently licensed proprietary applications of translational profiling technology from the University of California, San Francisco. Our scientific founders and management team comprise industry veterans who have played important roles in the discovery and development of marketed small molecule drugs, monoclonal antibody therapeutics and cellular immunotherapies in oncology and other disease areas.


Our leadership team’s in-depth understanding of translation regulation biology and oncology drug development is matched by our expertise in building and leading life science companies. This has given us our key advantage in pioneering the emerging field of translation regulation therapeutics and developing first-in-class agents in this pathway.

Chief Financial Officer
Chief Medical Officer
President and Chief Executive Officer
Vice President, Translational Science
Vice President, Development Operations
Vice President, Finance
Vice President, Preclinical Development and Clinical Pharmacology


Chief Operating Officer, Septerna
Former Chief Executive Officer, LWAC
Former Partner, Abingworth
Senior Vice President and Chief Commercial Officer, ADC Therapeutics
Former Chief Medical Officer, Sierra Oncology, Inc.
Former biotech company Chief Financial Officer and sell-side Analyst
President and Chief Executive Officer


Professor, Department of Cellular and Molecular Pharmacology, UCSF and Department of Chemistry, UC Berkeley Howard Hughes Medical Investigator
Professor, Department of Urology and Cellular & Molecular Pharmacology Helen Diller Family Endowed Chair in Basic Cancer Research, UCSF
Director of the Ludwig Center Louise Foote Pfeiffer Professor of Cell Biology Harvard Medical School
Patricia and James Cayne Chair for Junior Faculty Memorial Sloan Kettering Cancer Center
Former Head, Roche Oncology
Li Ka Shing Chancellor Chair and Professor of Biochemistry and Molecular Biology, UC Berkeley Howard Hughes Medical Investigator2020 Nobel Laureate in Chemistry
Chair, Department of Investigational Cancer Therapeutics Nellie B. Connally Chair in Breast Cancer MD Anderson Cancer Center
Enid A. Haupt Chair in Medical Oncology Memorial Sloan Kettering Cancer Center
Associate Director, NYU Cancer Institute Co-Director, Breast Cancer and Translational Cancer Research Albert B. Sabin Professor of Molecular Pathogenesis NYU School of Medicine